LB Pharmaceuticals (LBRX) announced the appointment of Kaya Pai Panandiker as Chief Commercial Officer, CCO. Before joining LB Pharmaceuticals, Pai Panandiker served as Chief Commercial Officer at Neumora Therapeutics (NMRA)
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LBRX:
- LB Pharmaceuticals Reports Strong Q3 and Strategic Progress
- LB Pharmaceuticals reports Q3 EPS (61c) vs ($39.49) last year
- LB Pharmaceuticals appoints Rawls as SVP of Regulatory Affairs
- Opening Day: Cerebras Systems withdraws IPO filing
- Buy Rating for LB Pharmaceuticals Driven by Promising LB-102 and Market Potential